Pharmaceutical multinational AstraZeneca intends to form a $1.5 billion production facility in Singapore to make antibody drug conjugates (ADCs).
ADCs are old in next-generation most cancers remedy.
Supported by way of the Financial Construction Board (EDB), this greenfield facility will likely be AstraZeneca’s first end-to-end ADC manufacturing web site, absolutely incorporating all steps of the difficult ADC production procedure at a business scale.
In step with the EDB, Prescription drugs & Biotechnology is a swiftly rising trade in Singapore, and is as soon as of 4 strategic sectors that Singapore has dedicated S$25 billion to folk sector analysis.
“We welcome AstraZeneca’s decision to establish a manufacturing presence in Singapore for the first time. It will also be a first for AstraZeneca – an end-to-end manufacturing facility for novel antibody drug conjugates that enables precision therapy for cancer. This greenfield investment is a strong show of confidence in Singapore’s biopharmaceutical manufacturing capabilities and talent, strengthens our ecosystem in supporting the development and manufacturing of precision medicines, and creates meaningful jobs and economic opportunities for Singapore. We look forward to a successful partnership with AstraZeneca.”
Png Cheong Boon – Chairman, EDB
The pharmaceutical sector employs 9,000 Singaporeans and produced over S$19 billion importance of export merchandise in 2022.
“AstraZeneca has built an industry- leading portfolio of cancer medicines including antibody drug conjugates which have shown enormous potential to replace traditional chemotherapy for patients across many settings. Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing, and I am excited for AstraZeneca to locate our $1.5 billion ADC manufacturing facility in the country.”
Pascal Soriot – CEO AstraZeneca
AstraZeneca goals to start out development of this production facility by way of the top of 2024, and can incorporate inexperienced answers in order that the ability will emit 0 carbon when it starts operation in 2029.
What are ADCs?
ADCs are biopharmaceutical (a drug made from organic resources) medication old in centered treatment in order potent cancer-killing brokers immediately via an antibody designed to focus on and blast a particular tumor mobile, restricting unwanted side effects.
The develop of ADCs is a multi-step procedure that incorporates antibody manufacturing, synthesis of chemotherapy drug (sometimes called the ‘warhead’) and linker, conjugation of drug-linker to the antibody, and filling of the finished ADC substance.
Featured symbol: AstraZeneca
